New atlas details immune cell changes as disease progresses
Researchers in Belgium have developed an atlas to mark changes in distinct types of immune cells during multiple myeloma’s  progression. Their work, in…
Myeloma
FDA to review combinations of Blenrep for multiple myeloma
The U.S. Food and Drug Administration (FDA) will review GSK’s request to approve Blenrep (belantamab mafodotin) as part of a combination treatment for adults…
November 19, 2024
by Marisa Wexler, MS
Survival better with Blenrep combo than Darzalex for R/R myeloma
A combination therapy using Blenrep (belantamab mafodotin) was more effective at extending life in people with relapsed or refractory multiple myeloma than a combo treatment…
Stem cell transplant is safe, effective in myeloma: Global real-world study
A standard autologous hematopoietic stem cell transplant (AHSCT) safely and effectively prolongs survival and delays cancer progression in adults with multiple myeloma, a…
Darzalex combo OK’d for multiple myeloma transplant-eligible patients
The subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) has been approved in the European Union as part of a combination treatment for adults with newly…
Darzalex combo up for EU approval for multiple myeloma patients
Johnson & Johnson (J&J) is asking regulatory authorities in the European Union to approve a combination treatment based on the subcutaneous, or under-the-skin, formulation…
Carvykti found effective at treating multiple myeloma in real world
Real-world treatment with the cell therapy Carvykti (ciltacabtagene autoleucel) was found to be highly effective among people with difficult-to-treat multiple myeloma in a multicenter…
New US approval sought for Darzalex Faspro quadruple therapy
Johnson & Johnson (J&J) is seeking U.S. Food and Drug Administration (FDA) approval for a quadruple treatment regimen based on Darzalex Faspro (daratumumab…
Carvykti lowering risk of death as second-line myeloma therapy: Trial
A single infusion of the cell therapy Carvykti (ciltacabtagene autoleucel) reduced the risk of death by 45% relative to standard treatment regimens for multiple…
FDA approves Sarclisa regimen as first-line treatment for myeloma
The U.S. Food and Drug Administration has approved Sanofi’s Sarclisa (isatuximab) in combination with standard-of-care treatment for adults with newly diagnosed multiple myeloma…
Recent Posts
- Study IDs ways IDH-related brain tumors become more aggressive
- Vulvar cancer possibly tied to bacteria not known in such cancers
- New atlas details immune cell changes as disease progresses
- FDA approves Imkeldi, imatinib as oral liquid, for certain leukemias
- Somatostatin may be safe option for certain tumors during pregnancy